Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396861 | 0.88 | HPGD (0.56) | DPP7HPGDAKR1C3MEN1KMT2A | |
| SCHEMBL30875692 | 0.88 | HPGD (0.56) | DPP7HPGDAKR1C3MEN1KMT2A | |
| SCHEMBL14590719 | 0.85 | DPP7 (0.59) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29987549 | 0.81 | DPP7 (0.52) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3196795 | 0.81 | DPP7 (0.55) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13485370 | 0.81 | DPP7 (0.58) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2634496 | 0.81 | DPP7 (0.52) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL28408084 | 0.81 | DPP7 (0.46) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17797648 | 0.81 | HPGD (0.51) | HPGDHSP90AA1AKR1C3MEN1KMT2A | |
| SCHEMBL13485294 | 0.78 | DPP7 (0.55) | DPP7NAMPTTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9505785-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2566869-B1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-8618107-B2 | Pyridone and aza-pyridone compounds and methods of use | GILEAD CONNECTICUT, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-5374643-A | Aryl urea (thiourea) and cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0587180-A2 | Aryl urea (Thiourea) and cyanoguanidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344040-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | DPP7 3343/4885NAMPT 629/4885TAS1R3 3025/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | DPP7 3343/4885NAMPT 629/4885TAS1R3 3025/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | DPP7 3343/4885NAMPT 629/4885TAS1R3 3025/4885 |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | DPP7 98/4885NAMPT 517/4885TAS1R3 4447/4885 |
| US-20180179229-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | DPP7 3343/4885NAMPT 629/4885TAS1R3 3025/4885 |
| US-10053469-B2 | Pyridone and aza-pyridone compounds and methods of use | PDXK, BTK, LCK | DPP7 3343/4885NAMPT 629/4885TAS1R3 3025/4885 |
| US-20170073356-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | DPP7 3080/4885NAMPT 645/4885TAS1R3 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.